Intimation under Regulation 30 of SEBI(Listing Obligations and Disclosure Requirement) Regulations 2015.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kimia Biosciences has been granted a 20-year patent by the Indian Patent Office for an improved manufacturing process of Luliconazole, an antifungal active pharmaceutical ingredient (API). Patent number 579384 was filed on January 9, 2022, and officially granted on January 29, 2026. The company stated that this strengthens its intellectual property portfolio in the antifungal API segment and is expected to enhance long-term business prospects. No financial figures or revenue impact estimates were disclosed in the filing.
Positive for the company in the long run as the patent provides exclusive rights to the improved Luliconazole manufacturing process for 20 years, potentially supporting pricing power and competitive positioning in the antifungal API market. However, the filing does not specify immediate revenue impact, so near-term stock movement may be limited.